The role of the PI3K/Akt/mTOR pathway in the development of resistance to standard anticancer therapy has been a recent focus of research and the inhibitors of the PI3K/AKT/mTOR pathway that restore sensitivity of cancers that have acquired resistance to standard therapy have been discussed [40]. The gene discussed is AKT1; the disease is cancer.